These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 35817567)

  • 1. Natural History of Friedreich Ataxia: Heterogeneity of Neurologic Progression and Consequences for Clinical Trial Design.
    Rummey C; Corben LA; Delatycki M; Wilmot G; Subramony SH; Corti M; Bushara K; Duquette A; Gomez C; Hoyle JC; Roxburgh R; Seeberger L; Yoon G; Mathews K; Zesiewicz T; Perlman S; Lynch DR
    Neurology; 2022 Oct; 99(14):e1499-e1510. PubMed ID: 35817567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Measuring the rate of progression in Friedreich ataxia: implications for clinical trial design.
    Friedman LS; Farmer JM; Perlman S; Wilmot G; Gomez CM; Bushara KO; Mathews KD; Subramony SH; Ashizawa T; Balcer LJ; Wilson RB; Lynch DR
    Mov Disord; 2010 Mar; 25(4):426-32. PubMed ID: 20063431
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluating mFARS in pediatric Friedreich's ataxia: Insights from the FACHILD study.
    Rummey C; Perlman S; Subramony SH; Farmer J; Lynch DR
    Ann Clin Transl Neurol; 2024 May; 11(5):1290-1300. PubMed ID: 38556905
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurologic outcomes in Friedreich ataxia: Study of a single-site cohort.
    Pandolfo M
    Neurol Genet; 2020 Jun; 6(3):e415. PubMed ID: 32337342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of loss of ambulation in Friedreich's ataxia.
    Rummey C; Farmer JM; Lynch DR
    EClinicalMedicine; 2020 Jan; 18():100213. PubMed ID: 31938785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Objective Assessment of Progression and Disease Characterization of Friedreich Ataxia via an Instrumented Drinking Cup: Preliminary Results.
    Krishna R; Pathirana PN; Horne MK; Szmulewicz DJ; Corben LA
    IEEE Trans Neural Syst Rehabil Eng; 2021; 29():2365-2377. PubMed ID: 34727035
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring progression in Friedreich ataxia (FRDA): the use of clinical scales.
    Bürk K; Schulz SR; Schulz JB
    J Neurochem; 2013 Aug; 126 Suppl 1():118-24. PubMed ID: 23859347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of the disease course in Friedreich ataxia.
    Hohenfeld C; Terstiege U; Dogan I; Giunti P; Parkinson MH; Mariotti C; Nanetti L; Fichera M; Durr A; Ewenczyk C; Boesch S; Nachbauer W; Klopstock T; Stendel C; Rodríguez de Rivera Garrido FJ; Schöls L; Hayer SN; Klockgether T; Giordano I; Didszun C; Rai M; Pandolfo M; Rauhut H; Schulz JB; Reetz K
    Sci Rep; 2022 Nov; 12(1):19173. PubMed ID: 36357508
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determining the Validity of Conducting Rating Scales in Friedreich Ataxia through Video.
    Tai G; Corben LA; Woodcock IR; Yiu EM; Delatycki MB
    Mov Disord Clin Pract; 2021 Jul; 8(5):688-693. PubMed ID: 34307740
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 2 year cohort study.
    Reetz K; Dogan I; Hilgers RD; Giunti P; Mariotti C; Durr A; Boesch S; Klopstock T; de Rivera FJR; Schöls L; Klockgether T; Bürk K; Rai M; Pandolfo M; Schulz JB;
    Lancet Neurol; 2016 Dec; 15(13):1346-1354. PubMed ID: 27839651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of rehabilitation intervention in persons with Friedreich ataxia.
    Paparella G; Stragà C; Vavla M; Pesenti N; Merotto V; Martorel GA; Zalunardo S; Armellin M; Comiotto J; Martinuzzi A
    Front Neurol; 2023; 14():1270296. PubMed ID: 38020600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Deferiprone in Friedreich ataxia: a 6-month randomized controlled trial.
    Pandolfo M; Arpa J; Delatycki MB; Le Quan Sang KH; Mariotti C; Munnich A; Sanz-Gallego I; Tai G; Tarnopolsky MA; Taroni F; Spino M; Tricta F
    Ann Neurol; 2014 Oct; 76(4):509-21. PubMed ID: 25112865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS): a 4-year cohort study.
    Reetz K; Dogan I; Hilgers RD; Giunti P; Parkinson MH; Mariotti C; Nanetti L; Durr A; Ewenczyk C; Boesch S; Nachbauer W; Klopstock T; Stendel C; Rodríguez de Rivera Garrido FJ; Rummey C; Schöls L; Hayer SN; Klockgether T; Giordano I; Didszun C; Rai M; Pandolfo M; Schulz JB;
    Lancet Neurol; 2021 May; 20(5):362-372. PubMed ID: 33770527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Open-label pilot study of oral methylprednisolone for the treatment of patients with friedreich ataxia.
    Patel M; Schadt K; McCormick A; Isaacs C; Dong YN; Lynch DR
    Muscle Nerve; 2019 Nov; 60(5):571-575. PubMed ID: 31206761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal study of the Friedreich Ataxia Impact Scale.
    Tai G; Yiu EM; Corben LA; Delatycki MB
    J Neurol Sci; 2015 May; 352(1-2):53-7. PubMed ID: 25840637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Very late-onset Friedreich ataxia despite large GAA triplet repeat expansions.
    Bidichandani SI; Garcia CA; Patel PI; Dimachkie MM
    Arch Neurol; 2000 Feb; 57(2):246-51. PubMed ID: 10681084
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Test-retest reliability of the Friedreich's ataxia rating scale.
    Rummey C; Zesiewicz TA; Perez-Lloret S; Farmer JM; Pandolfo M; Lynch DR
    Ann Clin Transl Neurol; 2020 Sep; 7(9):1708-1712. PubMed ID: 32779859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. How does performance of the Friedreich Ataxia Functional Composite compare to rating scales?
    Tai G; Yiu EM; Delatycki MB; Corben LA
    J Neurol; 2017 Aug; 264(8):1768-1776. PubMed ID: 28695363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biological and clinical characteristics of the European Friedreich's Ataxia Consortium for Translational Studies (EFACTS) cohort: a cross-sectional analysis of baseline data.
    Reetz K; Dogan I; Costa AS; Dafotakis M; Fedosov K; Giunti P; Parkinson MH; Sweeney MG; Mariotti C; Panzeri M; Nanetti L; Arpa J; Sanz-Gallego I; Durr A; Charles P; Boesch S; Nachbauer W; Klopstock T; Karin I; Depondt C; vom Hagen JM; Schöls L; Giordano IA; Klockgether T; Bürk K; Pandolfo M; Schulz JB
    Lancet Neurol; 2015 Feb; 14(2):174-82. PubMed ID: 25566998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.